

Summary of Product Characteristics for Pharmaceutical Products

1. Name of the medicinal product:

Malapip 40 mg/320 mg tablets

2. Qualitative and quantitative composition

Each film-coated tablet contains 20 mg dihydroartemisinin and 160 mg piperazine phosphate.

For product-specific information, see WHOPAR part 4.

3. Pharmaceutical form

Film-coated tablets

For product-specific information, see WHOPAR part 4.

4. Clinical particulars

4.1 Therapeutic indications

Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablet is indicated for the treatment of uncomplicated malaria. Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablet is active against all *Plasmodium* parasites that cause malaria in humans.

Treatment regimens should take into account the most recent official treatment guidelines (e.g. those of the WHO) and local information on the prevalence of resistance to antimalarial drugs.

4.2 Posology and method of administration

Posology

Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets should be administered over 3 consecutive days for a total of 3 doses taken at the same time each day.

Dosing should be based on body weight as shown in the following table:

Body weight	Number of tablets	Daily dose	
		Dihydroartemisinin	Piperazine phosphate
5 kg to less than 8 kg	1 tablet per day for 3 days	20 mg	160 mg
8 kg to less than 11 kg	1½ tablets per day for 3 days	30 mg	240 mg
11 kg to less than 17 kg	2 tablets per day for 3 days	40 mg	320 mg
17 kg to less than 25 kg	3 tablets per day for 3 days	60 mg	480 mg

This medicine is not recommended for infants below 5 kg in weight. Dispersible formulations may be preferred in children if available.

For patients weighing 25 kg or more, alternative formulations supplying higher amounts of active substance should be used.

When supplying this product to the patient, it is important to ensure that the pack size, i.e. the number of film-coated tablets supplied, is sufficient for a full treatment course according to the patient's weight.

Missed dose

If a dose is missed, it should be taken as soon as realised and then the recommended regimen continued until the full course of treatment has been completed.

Vomiting after administration

- If a patient vomits within 30 minutes of taking Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets, the whole dose should be re-administered;
- if a patient vomits within 30-60 minutes of administration, half the dose should be re-administered.

Re-dosing with Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets should not be attempted more than once. If the second dose is vomited, alternative antimalarial therapy should be started.

Repeated courses

There are no data on a second course of treatment.

No more than 2 courses of Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets may be given within a 12-month period (see sections 4.4 and 5.3).

A second course of Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets should not be given within 2 months after the first course due to the long elimination half-life of piperaquine (see sections 4.4 and 5.2).

Special populations

Elderly

Clinical studies of Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets did not include patients aged 65 years and over, therefore no dosing recommendation can be made. Considering the possibility of age-associated decrease in hepatic and renal function, as well as a potential for heart disorders (see sections 4.3 and 4.4), caution should be exercised when administering the product to the elderly.

Hepatic and renal impairment

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablet has not been evaluated in subjects with moderate or severe renal or hepatic insufficiency. Therefore, caution is advised when administering

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets to these patients (see section 4.4).

Method of administration

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets should be taken orally with water and without food (high fat meals can alter absorption of piperaquine):

- Each dose should be taken no less than 3 hours after the last food intake.
- No food should be taken within 3 hours after each dose.

For patients unable to swallow the film-coated tablets, Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets may be crushed and mixed with water. The mixture should be swallowed immediately after preparation.

4.3 Contraindications

- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
- Severe malaria according to WHO definition.
- Inherited long QT syndrome (congenital prolongation of the QTc interval) or a family history of this condition or of sudden death.
- Any other clinical condition known to prolong the QTc interval.
- History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
- Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction.
- Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.
- Taking medicinal products that are known to prolong the QTc interval. These include (but are not limited to):
 - o Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
 - o Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive medicinal products.
 - o Certain antimicrobial medicinal products, including medicinal products of the following classes:
 - macrolides (e.g. erythromycin, clarithromycin),
 - fluoroquinolones (e.g. moxifloxacin, sparflaxacin),
 - imidazole and triazole antifungal medicinal products,
 - pentamidine and saquinavir.
 - o Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine).
 - o Droperidol, domperidone, bepridil,

diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.

- Recent treatment with medicinal products known to prolong the QTc interval that may still be circulating at the time that Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablet is started, taking into account their elimination half-life (e.g. mefloquine, halofantrine, lumefantrine, chloroquine, quinine and other antimalarial medicinal products).

4.4 Special warnings and precautions for use

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets should not be used to treat complicated malaria.

The long half-life of piperaquine (about 22 days) should be kept in mind in the event that another antimalarial agent is started due to treatment failure or a new malaria infection (see below). In addition, piperaquine is an inhibitor and substrate of CYP3A4 and caution is needed if given with other medicinal products that affect or are metabolised via this system (see section 4.5).

In the absence of carcinogenicity study data, and due to lack of clinical experience with repeated courses of treatment in humans, no more than 2 courses of Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets should be given in a 12-month period (see section 5.3).

Effects on cardiac repolarisation

In clinical trials with dihydroartemisinin/piperaquine limited ECGs were obtained during treatment. These showed that QTc prolongation occurred more frequently and to a larger extent in association with dihydroartemisinin/piperaquine therapy than with the comparators (see section 5.1 for details of the comparators). Analysis of cardiac adverse events in clinical trials showed that these were reported more frequently in dihydroartemisinin/piperaquine-treated patients than in those treated with comparator antimalarial (see section 4.8). Before the third dose of dihydroartemisinin/piperaquine, in one of the two Phase III studies 3 out of 767 patients (0.4%) were reported to have a QTcF value of >500 milliseconds (ms) versus none in the comparator group.

The WHO guidelines no longer recommend performing an ECG before prescribing dihydroartemisinin/piperaquine. However, dihydroartemisinin/piperaquine should not be used in patients with known congenital long QT interval syndromes or those who have a clinical condition or are taking a medication that prolongs the QT interval.

There has been no evidence of piperaquine-related cardiotoxicity in large, randomised trials or in extensive deployment in the field.

Delayed haemolytic anaemia

Delayed haemolytic anaemia has been observed up to 1 month following use of intravenous artesunate and oral artemisinin-based combination treatment (ACT), including dihydroartemisinin/piperaquine. Some cases have been severe and required blood transfusion. Risk factors may include young age (children under 5 years old) and previous treatment with IV artesunate.

Patients and caregivers should be advised to be vigilant for signs and symptoms of post-treatment haemolysis such as pallor, jaundice, dark-coloured urine, fever, fatigue, shortness of breath, dizziness and confusion.

Furthermore, some patients with delayed haemolytic anaemia after dihydroartemisinin/piperaquine treatment show evidence of autoimmune haemolytic anaemia. Therefore, if available, a direct antiglobulin test (Coombs test) should be considered to determine whether treatment, e.g. with corticosteroids, is needed.

Paediatric population

Special precaution is advised in young children when vomiting, as they are likely to develop electrolyte disturbances. These may increase the QTc-prolonging effect of Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets.

Hepatic and renal impairment

Dihydroartemisinin/piperaquine has not been evaluated in patients with moderate or severe renal or hepatic insufficiency. Due to the potential for higher plasma concentrations of piperaquine to occur, caution is advised if Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablet is administered to patients with jaundice and/or with moderate or severe renal or hepatic insufficiency, and ECG and blood potassium monitoring are advised.

4.5 Interaction with other medicinal products and other forms of interaction

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg tablet is contraindicated in patients already taking other medicinal products that are known to prolong the QTc interval, due to the risk of an additive effect on the QTc interval (see section 4.3).

Piperaquine is a mild inhibitor of CYP3A4. Caution is recommended when co-administering

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets with *other medicines metabolised via CYP3A4*, as the therapeutic and/or toxic effects of some coadministered medicinal products could be altered.

Piperaquine is also a substrate of CYP3A4. A moderate increase of piperaquine plasma concentrations (<2-fold) has been noted when given with *strong CYP3A4 inhibitors*, resulting in a potential exacerbation of the effect on QTc prolongation (see below). Due to the lack of multiple dose PK data for piperaquine, administration of any strong CYP3A4 inhibitors should be discouraged after initiation (i.e. the first dose) of Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets (see section 5.2).

Exposure to piperazine may also be increased when co-administered with *mild or moderate CYP3A4 inhibitors* (e.g. oral contraceptives). Therefore, caution should be applied when co-administering

Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets with any CYP3A4-inhibitor and ECG monitoring should be considered.

A limited number of drug-drug pharmacokinetic interaction studies with Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets have been performed in healthy adult subjects. The assessment of the potential for drug-drug interactions to occur is therefore based on either *in vivo* or *in vitro* studies.

Effect of Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets on co-administered medicinal products

The concurrent administration of oral Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets with 7.5 mg oral *midazolam*, a CYP3A4 probe substrate, led to a modest increase (≤ 2 -fold) in midazolam and its metabolites exposure in healthy adult subjects. This inhibitory effect was no longer evident 1 week after last administration of Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets. Therefore, particular attention should be paid when medicinal products that have a narrow

therapeutic index (e.g. *antiretroviral medicinal products* and *ciclosporin*) are co-administered with

Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets.

From *in vitro* data, piperazine undergoes a low level of metabolism by CYP2C19, and is also an inhibitor of this enzyme. There is the potential for reducing the rate of metabolism of other substrates of this enzyme, such as *omeprazole*, with consequent increase of their plasma concentration, and therefore, of their toxicity.

Piperazine has the potential to increase the rate of metabolism for CYP2E1 substrates resulting in a decrease in the plasma concentrations of substrates such as *paracetamol* or *theophylline*, and the anaesthetic gases *enflurane*, *halothane* and *isoflurane*. The main consequence of this interaction could be a reduction of efficacy of the co-administered medicinal products.

When co-administered to healthy women, Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated tablets exerted only a minimum effect on an estrogen/progestogenic combination *oral contraceptive treatment*, increasing the rate of absorption of ethinylestradiol (expressed by geometric mean C_{max}) by about 28% but not significantly changing the exposure to ethinylestradiol and levonorgestrel and not influencing contraceptive activity as demonstrated by the similar plasma concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and progesterone observed after oral contraceptive treatment with or without concomitant Dihydroartemisinin/piperazine phosphate 20 mg/160 mg film-coated

tablets administration. For the possible need for ECG monitoring if the two medicines are given together, see above.

Dihydroartemisinin administration may result in a slight decrease in CYP1A2 activity. Caution is therefore, advised when Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablet is administered concomitantly with medicinal products metabolised by this enzyme that have a narrow therapeutic index, such as *theophylline*. Any effects are unlikely to persist beyond 24 hours after the last intake of dihydroartemisinin.

Effect of co-administered medicinal products on Dihydroartemisinin/piperaquine phosphate

20 mg/160 mg film-coated tablets

Piperaquine is metabolised by CYP3A4 *in vitro*. The concurrent administration of a single dose of oral *clarithromycin* (a strong CYP3A4 inhibitor probe) with a single dose of oral Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets led to a modest increase (≤ 2 -fold) in piperaquine exposure in healthy adult subjects. This increase in exposure to the antimalarial combination may result in an exacerbation of the effect on QTc. Therefore, particular caution is required if

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablet is administered to patients taking potent CYP3A4 inhibitors (e.g. some *protease inhibitors* [amprenavir, atazanavir, indinavir, nelfinavir, ritonavir], *nefazodone* or *verapamil*), and ECG monitoring should be considered due to the risk of higher plasma concentrations of piperaquine.

Enzyme-inducing medicinal products such as *rifampicin*, *carbamazepine*, *phenytoin*, *phenobarbital*, *St.*

John's wort (*Hypericum perforatum*) are likely to lead to reduced piperaquine plasma concentrations. The concentration of dihydroartemisinin may also be reduced. Concomitant treatment with such medicinal products is not recommended.

Paediatric population

Drug-drug interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known. The interactions documented above for adults should be considered for the paediatric population.

Food interaction

Absorption of piperaquine is increased in the presence of fatty food (see section 5.2) which may increase its effect on QTc interval. Therefore, Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets should be taken with water only, as described in section 4.2. Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets should not be taken with grapefruit juice as it is likely to lead to increased piperaquine plasma concentrations.

4.6 Pregnancy and Lactation

Pregnancy

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets may be used during the first trimester of pregnancy when the first-line option (artemether-lumefantrine) is not suitable or available.

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets can be used during the second and third trimester of pregnancy.

There are limited data on the use of dihydroartemisinin and piperaquine in pregnant women, particularly in the first trimester. Animal data has suggested a potential for birth defects and teratogenicity when dihydroartemisinin and piperaquine are administered during the first trimester of pregnancy (see section 5.3).

However, a meta-analysis of all exposures to artemisinin-based treatment (ABT) in the first trimester of pregnancy showed no differences between pregnancies exposed in the first trimester to artemisinin and those exposed to non-ABT in terms of the composite adverse pregnancy outcome (ABT=42/736 [5.7%] vs non-ABT=96/1074 [8.9%]; aHR: 0.71; 95% CI: 0.49–1.03). Analysis for adverse pregnancy outcomes against the individual parameters in the composite analysis, including miscarriage, stillbirth or congenital anomalies, also revealed no statistically significant difference. There was also no difference in the risk of these adverse pregnancy outcomes when exposures were restricted to the putative embryo-sensitive period. This analysis strengthens previous findings that the potential for artemisinin-based embryotoxicity observed in animal studies is not reflected in humans treated for malaria although few exposures in the first trimester of pregnancy can be documented.

Dihydroartemisinin+piperaquine phosphate was used successfully in the second and third trimesters of pregnancy in more than 2000 women on the Myanmar–Thailand border for rescue therapy and in Indonesia for first-line treatment. WHO guidelines consider that experience with artemisinin derivatives in the second and third trimesters (over 4000 documented pregnancies) is increasingly reassuring.

Breastfeeding

Animal data suggest excretion of piperaquine into breast milk, but the amounts that enter breast milk and are consumed by breastfeeding infants are expected to be relatively small. In line with WHO guidelines,

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg film-coated tablets can be used in breastfeeding women.

Fertility

There are no specific data relating to the effects of piperaquine on fertility, however, to date no adverse events have been reported during clinical use. Data obtained in animal studies show that fertility is unaffected by dihydroartemisinin in both females and males.

4.7 Effects on ability to drive and use machines

Dihydroartemisinin/piperaquine phosphate 20 mg/160 mg tablet is unlikely to affect the ability to drive or operate machinery.

However, patients should be advised to consider if their clinical status, including any undesirable effects of the medicine, allows them to perform skilled tasks safely.

4.8 Undesirable effects

Summary of the safety profile

The safety of dihydroartemisinin/piperaquine has been evaluated in 2 phase III open-label studies involving 1,239 paediatric patients up to 18 years and 566 adult patients over 18 years treated with dihydroartemisinin/piperaquine.

In a randomised trial in which 767 adults and children with uncomplicated *P. falciparum* malaria were exposed to dihydroartemisinin/piperaquine, 25% of subjects were judged to have experienced an adverse drug reaction (ADR). No single type of ADR occurred at an incidence of $\geq 5\%$.

The most frequent ADRs observed at an incidence $\geq 1.0\%$ were: headache (3.9%), electrocardiogram QTc prolonged (3.4%), *P. falciparum* infection (3.0%), anaemia (2.8%), eosinophilia (1.7%), haemoglobin

decreased (1.7%), sinus tachycardia (1.7%), asthenia (1.6%), haematocrit [decreased] (1.6%), pyrexia (1.5%), red blood cell count decreased (1.4%). A total of 6 (0.8%) subjects had serious ADRs in the study.

In a second randomised trial, 1,038 children, aged between 6 months and 5 years, were exposed to dihydroartemisinin/piperaquine and 71% were judged to have experienced an ADR. The following ADRs were observed at an incidence of $\geq 5.0\%$: cough (32%), pyrexia (22.4%), influenza (16.0%), *P. falciparum* infection (14.1%), diarrhoea (9.4%), vomiting (5.5%) and anorexia (5.2%). A total of 15 (1.5%) subjects had serious ADRs in the study.

The ADRs noted for dihydroartemisinin/piperaquine in these trials were generally mild in severity, and the majority were non-serious. Reactions such as cough, pyrexia, headache, *P. falciparum* infection, anaemia, asthenia, anorexia and the observed changes in blood cell parameters are consistent with those expected in patients with acute malaria.

Tabulated list of adverse reactions

The undesirable effects of dihydroartemisinin/piperaquine are listed below by body system or organ.

Frequencies are defined as very common (at least 1 in 10), common (1 in 100 to 1 in 10), uncommon (1 in 1000 to 1 in 100), rare (1 in 10 000 to 1 in 1000), very rare (less than 1 in 10 000) or not known (frequency cannot be estimated from available data).

ADRs in adult patients participating in clinical studies with dihydroartemisinin/piperaquine and post-marketing data:

Infections and infestations	
Common	<i>P. falciparum</i> infection
Uncommon	respiratory tract infection; influenza
Blood and lymphatic disorders	
Common	anaemia
Not known	autoimmune haemolytic anaemia, delayed haemolytic anaemia
Metabolic and nutrition disorders	
Uncommon	anorexia
Nervous system disorders	
Common	headache
Uncommon	convulsion; dizziness
Cardiac disorders	
Common	QTc interval prolongation; tachycardia
Uncommon	cardiac conduction disorders; sinus arrhythmia; bradycardia
Respiratory disorders	
Uncommon	cough
Gastrointestinal disorders	
Uncommon	vomiting; diarrhoea; nausea; abdominal pain
Hepatobiliary disorders	
Uncommon	hepatitis; hepatocellular injury, hepatomegaly; abnormal liver function tests
Skin and subcutaneous tissue disorders	
Uncommon	pruritis
Musculoskeletal and connective tissue disorders	
Uncommon	arthralgia; myalgia
General disorders and administration site conditions	
Common	asthenia; pyrexia

Description of selected adverse reactions

The effect on prolongation of the QTc interval was observed on Day 2 and had resolved by Day 7 (the next time point at which ECGs were performed).

Paediatric population

A tabular overview of the frequency of the ADRs in paediatric patients is given below. The majority of paediatric experience is derived from African children aged 6 months to 5 years.

ADRs in paediatric patients participating in clinical studies with dihydroartemisinin/piperaquine and post-marketing data:

Infections and infestations	
Very common	influenza; <i>P. falciparum</i> infection
Common	respiratory tract infection; ear infection

Blood and lymphatic disorders	
Common	thrombocytopenia; leukopenia/neutropenia; leukocytosis; anaemia
Uncommon	thrombocytosis; splenomegaly; lymphadenopathy; hypochromasia
Not known	autoimmune haemolytic anaemia, delayed haemolytic anaemia
Metabolic and nutrition disorders	
Common	anorexia
Nervous system disorders	
Uncommon	convulsion; headache
Eye disorders	
Common	conjunctivitis
Cardiac disorders	
Common	QTc interval prolongation; irregular heart rate
Uncommon	cardiac conduction disorders; cardiac murmur
Respiratory disorders	
Very common	cough
Uncommon	rhinorrhoea; epistaxis
Gastrointestinal disorders	
Common	vomiting; diarrhoea; abdominal pain
Uncommon	stomatitis; nausea
Hepatobiliary disorders	
Uncommon	hepatitis; hepatomegaly; abnormal liver function tests; jaundice
Skin and subcutaneous tissue disorders	
Common	dermatitis; rash
Uncommon	acanthosis; pruritis
Musculoskeletal and connective tissue disorders	
Uncommon	arthralgia
General disorders and administration site conditions	
Very common	pyrexia
Common	asthenia

Reporting of suspected adverse reactions

Health care providers are asked to report adverse reactions that may be linked to a medicine, to the marketing authorisation holder, or, if available, to the national reporting system. Reports of suspected adverse reactions to a medicine are important for the monitoring of the medicine's benefits and risks.

4.9 Overdose

In clinical trials, 9 patients received double the cumulative intended dose of dihydroartemisinin/piperaquine.

The safety profile of these patients did not differ from that of patients receiving the recommended dose, with no patient reporting SAEs.

In cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate, including ECG monitoring because of the possibility of QTc interval prolongation (see section 4.4).

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antiprotozoals, antimalarials, artemisinin and derivatives, combinations, ATC code: P01BF05

Pharmacodynamic effects

Dihydroartemisinin is able to reach high concentrations within the parasitized erythrocytes. Its endoperoxide bridge is thought to be essential for its antimalarial activity, causing free-radical damage to parasite membrane systems including:

- Inhibition of *falciparum* sarcoplasmic-endoplasmic reticulum calcium ATPase
- Interference with mitochondrial electron transport
- Interference with parasite transport proteins
- Disruption of parasite mitochondrial function

The exact mechanism of action of piperazine is unknown, but it likely mirrors that of chloroquine, a close structural analogue. Chloroquine binds to toxic haem (derived from the patient's haemoglobin) within the malaria parasite, preventing its detoxification via a polymerisation step.

Piperazine is a bisquinolone, and this class has shown good antimalarial activity against chloroquine-resistant *Plasmodium* strains *in vitro*. The bulky bisquinolone structure may be important for activity against chloroquine-resistant strains, and may act through the following mechanisms:

- Inhibition of the transporters that efflux chloroquine from the parasite food vacuole
- Inhibition of haem-digestion pathway in the parasite food vacuole

Resistance to piperazine (when used as monotherapy) has been reported.

The efficacy and safety of dihydroartemisinin/piperazine have been assessed in two large randomised, open-label clinical trials:

Study DM040010 was conducted in Asian adult and paediatric patients with uncomplicated *P. falciparum* malaria. Dihydroartemisinin/piperazine (DHA/PPQ) treatment was compared with Artesunate +

Mefloquine (AS + MQ). The primary endpoint was the PCR-corrected cure rate at Day 63.

Study DM040011 was conducted in African paediatric patients with uncomplicated *P. falciparum* malaria.

Dihydroartemisinin/piperaquine (DHA/PPQ) treatment was compared with Artemether + Lumefantrine (A + L). The primary endpoint was PCR-corrected cure rate at Day 28.

The results for the primary endpoint in the modified intent to treat (m-ITT) populations (defined as all randomised patients who received at least one dose of the study treatment, with the exclusion of those patients lost to follow up for unknown reasons) were as follows:

Study	PCR-corrected cure rate (m-ITT)			95 % two-sided CI on the treatment difference (DHA/PPQ - Comparator)
	DHA/PPQ	AS+MQ	A+L	
DM040010 (n=1087)	97.0%	95.3%	-	(-0.84, 4.19) %; p=0.161
DM040011 (n=1524)	92.7%	-	94.8%	(-4.59, 0.45) %; p=0.128

In each case the results confirmed that DHA/PPQ was not inferior to the comparator medicinal product. In both studies, the true treatment failure rate was below the 5% efficacy threshold set by WHO.

The age-specific PCR-corrected cure rates in the m-ITT populations are tabulated below for the Asian and African studies, respectively:

Study	PCR-corrected cure rate (m-ITT)			95 % two-sided CI on the treatment difference (DHA/PPQ - Comparator)
	DHA/PPQ	AS+MQ	A+L	
DM04010 (n=1087)				
≤5 years	100.0%	100.0%	-	-
>5 to ≤12 years	98.2%	96.5%	-	(-3.67, 7.09) %; p=0.605
>12 to ≤18 years	97.3%	100.0%	-	(-6.40, 0.99) %; p=1.000
>18 to ≤64 years	96.6%	94.4%	-	(-0.98, 5.30) %; p=0.146
DM04011 (n=1524)				
≤1 year	91.5%	-	98.5%	(-12.66, -1.32) % ⁽¹⁾ ; p=0.064
>1 to ≤2 years	92.6%	-	94.6%	(-6.76, 2.63) %; p=0.413
>2 to ≤5 years	93.0%	-	94.0%	(-4.41, 2.47) %; p=0.590

(1) This CI is asymptotic because the exact CI could not be computed.

5.2 Pharmacokinetic properties

Further information on pharmacokinetic properties is shown in the product information as approved by the reference authority, stated in WHOPAR part 1.

	Dihydroartemisinin	Piperaquine
General	Bioavailability is higher in patients with malaria compared to healthy volunteers.	
Absorption		
Absolute bioavailability	NA	NA
Oral Bioavailability	NA	NA
Food effect	Exposure increased by 43% with a high fat/high calorie meal	Exposure increased approximately 3-fold with a high fat/high calorie meal
Distribution		
Volume of distribution (mean)	0.8 L/kg	730 L/kg
Plasma protein binding <i>in vitro</i>	44–93%	> 99%
Tissue distribution	Accumulates in red blood cells	Accumulates in red blood cells
Metabolism		
	Hepatic glucuronidation to α -artenimol- β -glucuronide	Hepatic: major metabolites are a carboxyl acid cleavage product and a mono-N-oxidated product
Elimination		
Mean elimination half-life	1 hour	22 days
Mean oral clearance	1.34 L/h/kg	2.1 L/h/kg
% of dose excreted in urine	Negligible as intact drug	NA
% of dose excreted in faeces	Negligible as intact drug	NA
Pharmacokinetic linearity	NA	NA
Drug interactions (<i>in vitro</i>)		
Transporters	NA	NA
Metabolising enzymes	UGT1A9 and UGT2B7	CYP3A4 (mainly), CYP2C9 and CYP2C19
	Inhibitor of CYP1A2	Mild inhibitor of CYP3A4 and CYP2C19
		Inducer of CYP2E1
Special populations		
Renal impairment	NA	NA
Hepatic impairment	NA	NA
Elderly patients	NA	NA

NA: Not available

Patients with hepatic or renal insufficiency

No specific pharmacokinetic studies have been performed in patients with hepatic or renal insufficiency, or in elderly people.

Paediatrics

In a paediatric pharmacokinetic study, and based on very limited sampling, minor differences were observed for dihydroartemisinin pharmacokinetics between the paediatric and adult populations. The mean clearance (1.45 L/h/kg) was slightly faster in the paediatric patients than in the adult patients (1.34 L/h/kg), while the mean volume of distribution in the paediatric patients (0.705 L/kg) was lower than in the adults (0.801 L/kg).

The same comparison showed that piperaquine absorption rate constant and terminal half-life in children were predominantly similar to those seen in adults. However, the apparent clearance was faster (1.30 versus 1.14 L/h/kg) and the apparent total volume of distribution was lower in the paediatric population (623 versus 730 L/kg).

5.3 Preclinical safety data

General toxicity

Literature data concerning chronic toxicity of piperaquine in dogs and monkeys indicate some hepatotoxicity and mild reversible depression of total white cell and neutrophil counts.

The most important nonclinical safety findings after repeated dosing were the infiltration of macrophages with intracytoplasmic basophilic granular material consistent with phospholipidosis and degenerative lesions in numerous organs and tissues. These adverse reactions were seen in animals at exposure levels similar to

clinical exposure levels, and with possible relevance to clinical use. It is not known whether these toxic effects are reversible.

Dihydroartemisinin and piperaquine were not genotoxic/clastogenic based on *in vitro* and *in vivo* testing.

No carcinogenicity studies have been performed.

Dihydroartemisinin causes embryoletality and teratogenicity in rats and rabbits.

Piperaquine did not induce malformation in rats and rabbits. In a perinatal and postnatal development study (segment III) in female rats treated with 80 mg/kg, some animals had a delay of delivery inducing mortality of the neonates. In females delivering normally, the development, behaviour and growth of the surviving progeny was normal following exposure *in utero* or via milk.

No reproduction toxicity studies have been performed with the combination of dihydroartemisinin and piperaquine.

Central nervous system (CNS) toxicity

There is potential for neurotoxicity of artemisinin derivatives in man and animals, which is strongly related to the dose, route and formulations of the different dihydroartemisinin pro-drugs. In humans, the potential neurotoxicity of orally administered dihydroartemisinin can be considered highly unlikely, given the rapid clearance of dihydroartemisinin, and its short exposure (3 days of treatment for malaria patients). There was no evidence of dihydroartemisinin-induced lesions in the specific nuclei in rats or dogs, even at lethal dose.

Cardiovascular toxicity

Effects on blood pressure and on PR and QRS duration were observed at high piperazine doses. The most important potential cardiac effect was related to cardiac conduction.

In the hERG test, the IC₅₀ was 0.15 µmol for piperazine and 7.7 µmol for dihydroartemisinin. The association of dihydroartemisinin and piperazine does not produce hERG inhibition greater than that of the single compounds.

Phototoxicity

There are no phototoxicity concerns with dihydroartemisinin, as it does not absorb in the range of 290– 700 nm. Piperazine has an absorption maximum at 352 nm. Since piperazine is present in the skin (about 9% in the non-pigmented rat and only 3% in the pigmented rat), slight phototoxic reactions (swelling and erythema) were observed 24 hours after oral treatment in mice exposed to UV radiation.

6. Pharmaceutical Particulars

Information on the pharmaceutical particulars is shown in the product information as approved by the reference authority, stated in WHOPAR part 1.

6.1 List of Excipients

6.2 Incompatibilities

6.3 Shelf-Life

6.4 Special Precautions for storage

6.5 Nature and Content of container

6.6 Special precautions for disposal and other handling

7. Marketing Authorization Holder

Information on the supplier is shown in the product information as approved by the reference authority, stated in WHOPAR part 1.

8. Marketing Authorization Number

CTD7841/14997

9. Date of first authorization/renewal of the authorization

2021 September 16

10. Date of revision of the text

2021 September 16